Rocket Pharmaceuticals (RCKT) Misses Q4 EPS by 15c
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Clear Street Starts SpaceX (SPCX) at Buy
- S&P Global (SPGI) PT Lowered to $510 at RBC Capital Following Mobility Spin
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
